Mar 18 2011
ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today that the Company has frozen its Endoluminal Occlusion (EOS) device design for the peripheral category of indications in preparation for the Company's regulatory phase, prior to commercialization in Europe and North America and subsequent to venturing forward into Eastern Europe, Japan, Asia Pacific and Latin America.
"This is another milestone in the Company's growth and moves the Company one step closer to its targeted 2011 European commercialization of the EOS device," said Jim Graham, CEO, ArtVentive Medical Group, Inc. "We are pleased with the compounding success that we have experienced and we look forward to the continued expansion of our family of EOS devices."
Source: ArtVentive Medical Group, Inc.